Sunday, October 13, 2024 from 2:15 PM to 3:45 PM MST at Convention Center North Building / Meeting Room 132
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-24-194-L02-PActivity Type: A Knowledge-Based ActivityAuthors of the recently published expert consensus recommendations on the use of novel and long-acting antiretroviral therapy will provide perspective on the consensus process, use and monitoring of agents, and strategies for optimization of patient outcomes.
Learning Objectives1. Describe the Modified Delphi Technique as a consensus-building methodology.
2. Outline the efficacy and safety data of novel antiretroviral agents in patients who are heavily treatment-experienced and multidrug-resistant HIV-1.
3. Explore how disparities or barriers may influence the selection of novel antiretroviral agents for heavily treatment-experienced and multidrug-resistant HIV-1 patients.
4. Define the optimal therapeutic role of novel antiretroviral agents in patients with multidrug-resistant or heavily treatment-experienced HIV.
5. Discuss the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) rating system in achieving consensus recommendations.
6. Highlight pertinent safety and efficacy data on long-acting antiretrovirals in the treatment and prevention of HIV-1.7. Describe the optimal role and monitoring of long-acting antiretrovirals in the treatment and prevention of HIV-1.
8. Define strategies to support adherence to long-acting antiretrovirals for HIV-treatment and preexposure prophylaxis.
 | | Speaker: | David B. Cluck, Pharm.D., BCIDP, BCPS, AAHIVP | | Associate Professor
East Tennessee State University
Department of Pharmacy Practice
Johnson City, TN | | View Biography |
|
 | | Speaker: | Melissa E. Badowski, Pharm.D., MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP | | Clinical Professor/Associate Director of Clinical Pharmacy Services in Ambulatory Care
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois | | View Biography |
|